



Europäisches Patentamt
European Patent Office
Office européen des brevets

(3) Publication number: 0 592 870 A1

EUROPEAN PATENT APPLICATION

(4) Application number: 93115730.9

(5) Date of filing: 29.09.93

A request for addition of the description has been filed pursuant to Rule 88 EPC. A decision on the request will be taken during the proceedings before the Examining Division (Guidelines for Examination in the EPC, A-V, 2.2).

(6) Priority: 30.09.92 US 954906

(7) Date of publication of application: 20.04.94 Bulletin 94/16

(8) Designated Contracting States: BE DE ES FR GB NL

(9) Applicant: C.R. BARD, INC.
730 Central Avenue
Murray Hill New Jersey 07974(US)

(10) Inventor: Tedeschi, Eugene
216 Still River Road
Still River, Mass.(US)
Inventor: Elton, Richard K.
8 Wing Street
Glens Falls, N.Y.(US)

(11) Representative: Laufhütte, Dieter, Dr.-Ing. et al
Lorenz-Seldner-Gossel
Wildenmayerstrasse 23
D-40538 MÜNCHEN (DE)

(12) Process for preparing functionally coated expanded products from expandable tubing and the expanded products produced thereby.

(13) A process for preparing expanded thermoplastic medical products (e.g., dilatation balloons) having biomedical functional coatings such as lubricous coatings or protective coatings is disclosed. The process involves the steps of coating a suitable expandable thermoplastic tubing with the biomedical functional coating, at least partially drying the coated tubing, and then stretching and expanding the coated tubing. The coating comprises at least one functional agent (e.g., poly(ethylene oxide), a hydrophilic polyurethane or polysiloxane) dispersed, or emulsified in a carrier such as water and/or an organic solvent. Conventional fabricating procedures are used for stretching and expanding the coated tubing. Optional steps may include a heating step during stretching and expansion. The coated products produced by this process have a uniformly functional coating.

Rank Xerox (UK) Business Services
0.1013.93/3.1.4

BEST AVAILABLE COPY

EP 0 592 870 A1

BACKGROUND OF THE INVENTION

This invention relates to expanded thermoplastic medical products, particularly to a novel process for preparing an expanded thermoplastic medical product having a functional biomedical coating adhered to the expanded surface, particularly coated balloons for use on catheters.

The prior art process for applying functional coatings to balloons utilizes the step of applying the coating to the pre-formed balloon, i.e., to the blow molded balloon. Preferably the coating is applied to the inflated pre-formed balloon. Applying the coating to the inflated balloon allows the formation of a coating layer having a generally uniform thickness. A typical coating procedure is described at Col. 4, lines 48-54 and exemplified at Col. 5, lines 41-44 of U.S. 5,028,607 (issued June 25, 1991 to M. Klezulas). The dilatation balloons are first formed from the appropriate tubing by a series of stretching, optionally heating, and expanding operations such as blow molding. Then the balloon is bonded to an appropriate catheter shaft using an adhesive or other appropriate means. Alternatively the tubing may be an integral part of the catheter. Finally, the functional coatings are applied, typically by dipping or spraying. The coated surface is allowed to dry and cured if necessary.

Current functional coatings used on pre-formed balloons are generally limited to water borne dispersions and emulsions because most organic solvents tend to permeate the thin wall of the balloon and alter the physical properties, e.g., by changing the polymer crystallinity.

There are several disadvantages to coating processes which involve applying the functional coating to a pre-formed balloon. These disadvantages include the following:

(i) the coating thicknesses on irregularly shaped objects can be inconsistent due to non-uniform drainage of the coating solution as it flows off the coated object, and some balloon geometries may promote entrapment of air during coating, thus producing a product with cosmetic irregularities;

(ii) pre-formed balloons are highly oriented and crystalline and thus are very sensitive to changes caused by contact with the solvents present in some coating solutions; and are also sensitive to any heating operations that may be required for curing a coating or driving off solvent from the coating solution;

(iii) to minimize the effect of solvent exposure on pre-formed balloons it may be necessary to apply the coating by spraying rather than dipping. In which case there are safety concerns with flammability, exposure to the finely divided solvent mist, and unwanted side effects on the

coating due to evaporative cooling of the finely divided droplets formed during spraying; and (iv) the high value loss of coated pre-formed balloons and coated finished catheters which are caused by coating errors.

SUMMARY OF THE INVENTION

It is an object of the invention to coat an expandable thermoplastic tubing material suitable for a medical product with a coating containing a functional biomedical material and a carrier and to then expand the coated tubing to form an expanded medical product with an adherent coating of the functional biomedical material.

It is also an object of this invention to coat an expandable thermoplastic tubing suitable for forming a balloon with a coating which contains a functional biomedical material and to expand the coated tubing to form an expanded balloon with a uniformly functional, highly adherent coating on its outer surface.

It is a further object of the invention to coat an expandable thermoplastic tubing suitable for blow molding a dilatation balloon with a lubricous coating and to blow mold the coated tubing to form a lubricious dilatation balloon.

The present invention provides a process for preparing a coated expanded thermoplastic medical product. The process comprises the steps of:

(a) applying to at least a portion of an inner and/or an outer surface of an expandable thermoplastic tubing at least one adherent functional biomedical coating which comprises at least one functional agent and a carrier;

(b) allowing the coated tubing to dry at a time and temperature sufficient to remove at least part of the carrier; and

(c) stretching and/or expanding the dried coated tubing with an inflating fluid at a pressure sufficient to form the functionally coated expanded medical product. The expanded thermoplastic medical products prepared by this process are uniformly functionally coated.

The present invention provides a process for preparing a coated balloon. The process comprises the steps of:

(a) applying to at least a portion of an inner and/or an outer surface of an expandable thermoplastic tubing at least one adherent functional biomedical coating which comprises at least one functional agent and a carrier;

(b) allowing the coated tubing to dry at a time and temperature sufficient to remove at least part of the carrier; and

(c) stretching and/or expanding the dried coated tubing with an inflating fluid at a pressure sufficient to form the functionally coated balloon.

EP 0 592 870 A1

The balloons prepared by this process are uniformly functionally coated.

The present invention also provides a process for preparing a lubricious dilatation balloon. The process comprises the steps of:

- (a) applying to at least a portion of an outer surface of an expandable thermoplastic tubing at least one adherent functional biomedical coating which comprises (i) one or more carriers, (ii) a poly(ethylene oxide) dissolved, dispersed, or emulsified in the carrier, and (iii) a polymer selected from the group consisting of a polyurethane, a polyurea, and a polyurethane-urea or polymer precursors selected from the group consisting of polyurethane precursors and polyurea precursors, the polymer or polymer precursors being dissolved, dispersed, or emulsified in the carrier(s);

- (b) allowing the coated tubing to dry at a time and temperature sufficient to remove at least part of the carrier; and
- (c) expanding the coated tubing with an inflating fluid in order to increase the diameter and length of the tubing while simultaneously orienting the tubing. The lubricious dilatation balloons prepared by this process are uniformly functionally coated.

As used herein, the term "thermoplastic" is exclusive of natural or synthetic rubbers. It is understood that thermoplastic materials which can be formed into a tube, coated, and then subjected to further heat treatment to cure the coating and/or the tubing and form a thermoset tube are also suitable for use herein.

As used herein, the term "functional biomedical coating" is used for coatings applied to medical products intended for use in the body. Such coatings are usually, but not necessarily activated in an aqueous environment, and they provide (i) protective properties such as abrasion resistance, puncture resistance and/or tear resistance, (ii) functional properties such as lubricity, thromboresistance, hemocompatibility, and (iii) therapeutic properties such as anti-thrombogenic properties, antimicrobial properties and the like, and like functional improvements. The functional biomedical coatings useful herein must exhibit adhesion suitable for the intended end use of the medical product and they should have the potential for reasonably high radial and circumferential stretching.

The carriers used for the coatings can be either an organic solvent or water, with the choice depending on the coating components and on the thermoplastic tubing material being coated. In some cases one or more organic solvents may be used, whereas in other cases water may be used as the carrier. Suitable solvents are those which do not adversely affect stretching and expanding steps

which are used to form the final expanded product from the coated tubing. Suitable solvents include alcohols such as ethanol or ethylene glycol; ketones such as methyl ethyl ketone; esters such as ethylene glycol methyl ether; esters such as ethyl acetate; ether acetates such as ethylene glycol monoethyl ether acetate; aromatic and aliphatic solvents such as benzene, toluene, xylene, N-methylpyrrolidone, and pyridine; nitroaromatics such as 2-nitropropane; chlorinated solvents such as methylene chloride, methylene bromide, trichloroethylene, ethylene dichloride, and mixtures of the above. The chlorinated solvents are particularly useful for poly(ethylene oxide) containing coatings.

The ability to maintain a continuous coating over the surface of the thus-expanded balloon, even after the radial and circumferential stretching of several hundred percent which is involved in expanding the balloon, is highly advantageous.

Applying the functional biomedical coating to the expandable thermoplastic tubing prior to expansion provides the following advantages:

- (i) It is possible to coat the tubing using solvents which would otherwise attack and deform a pre-formed polymeric material such as a dilatation balloon, thus greatly broadening the range of coatings which can be used;
- (ii) It is much less expensive to discard rejected coated tubing than to discard rejected coated pre-formed objects such as catheter balloons or assembled catheters with attached balloons;
- (iii) It is much easier to control the uniformity of the resulting coating because the material being coated, i.e., the tubing is a simple cylinder rather than a pre-formed object, such as a balloon, with a potentially complex geometry;

- (iv) It is possible to readily cure coatings requiring elevated temperatures because the tubing, unlike pre-formed expanded products such as dilatation balloons or assembled products, can tolerate the significantly higher temperatures required to cure many coating compositions;

- (v) separately coating the components of a multi-component device allows one to produce a device with different performance properties for each component, depending upon the coating used on each component, and this cannot be obtained if one is limited to coating the entire multi-component device; and

- (vi) separately coating the individual components of a multi-component device tends itself to more efficient production because it allows simultaneous manufacturing steps to occur in parallel rather than in series.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The expandable thermoplastic tubings to be coated include tubings made from the materials typically used to form expanded products such as dilatation balloons, esophageal dilatation balloons, fallopian tube dilatation balloons, peripheral angioplasty dilatation balloons, prostate dilatation balloons, coronary angioplasty balloons, uterine manipulator balloons and the like. Included among the suitable thermoplastic materials are polyurethanes, polyethylene, ethylene-butylene-styrene, polypropylene, polyethylene terephthalate or block copolymers thereof admixed with low molecular weight styrene and optionally polypropylene, and similar compositions employing butadiene or isoprene in place of the ethylene and butylene; polyvinyl chloride; copolymers; silicone polycarbonate vinyl chloride; copolymers; silicone copolymers; copolymers; ethylene-vinyl acetate copolymers; polyether polyamide block copolymers such as Sur-Pax®; polycarbonates; ionomers such as Surlyn®; polybutylene terephthalate, polyarylether ketones; polyimides; polyamides, particularly aromatic polyamides; polyimides, polyetherimides; polyamideimides; and the like. One skilled in the art will consider such factors as processability, performance parameters required for the balloon, coating adhesion, and biocompatibility in making the appropriate selection.

The choice of dilatation balloon material will depend on the particular application. For example, some applications will require a rigid non-compliant polymer, while other applications will favor the use of a softer polymer.

Segmented polyurethanes are suitable as thermoplastic tubing materials for dilatation balloons. Segmented polyurethanes can be varied by using different isocyanates and polyols and different ratios of hard to soft segments in the polymer. The hard to soft ratio defines the expansion capabilities of the balloon as well as its elasticity. If the segmented polyurethane to be coated is a hard polymer, then preferably a hard polymer should be used in the functional coating. If the segmented polyurethane to be coated is a soft polymer, then preferably a softer polymer should be used in the functional coating. Of particular interest for dilatation balloons are certain PELLETHANE® polyurethane polymers (e.g., PELLETHANE® 2387-75D).

Also particularly suitable as thermoplastic tubing materials for dilatation balloons are polyethylene terephthalates (PET), particularly high molecular weight homopolymers of PET and PET copolymers. Balloons made from PET tend to be highly rigid when inflated and are capable of sustaining high inflation pressures even when the balloon wall thickness is thin, e.g., less than 0.002".

Similarly, there is a wide range of functional biomedical coatings which can be adapted for use in this process. The choice of coating will depend on factors such as the function desired (i.e., lubricity, hemocompatibility, antimicrobial properties, etc.), the ability of a particular coating to bond to the thermoplastic tubing material, the ability of the coating to endure the stretching and/or expanding process, durability (e.g., abrasion resistance) required of the coating in its intended application, and the like. One skilled in the art of coating will weigh these factors in making an appropriate choice.

Coatings containing poly(ethylene oxide) are desirable because poly(ethylene oxide) has the desired functional characteristic of "passivating" a surface toward platelets and it is quite non-thrombogenic. See Chapter 4 "Poly(ethylene oxide) and Related Hydrogels" by Neil B. Graham (pp. 95-113) in "Hydrogels in Medicine and Pharmacy", Vol. II Polymers, ed. by N. A. Peppas, CRC Press, Inc., Boca Raton, Florida, 1986.

Such coatings provide a combination of useful properties, namely, lubricity, biocompatibility and, when complexed with a crosslinking polymer, a high degree of durability. These properties are particularly useful and sought after in dilatation balloons.

Functional biomedical coatings containing poly(ethylene oxide) and pre-formed polyurethanes, polyureas, or polyurethaneureas are particularly useful, as are coatings containing poly(ethylene oxide) and polyurea precursors. Preferred coatings contain poly(ethylene oxide) blended with polyurethane precursors which are polymerized and crosslinked *in situ* on the coated surface.

Particularly preferred for applications requiring permanent lubricity, coating durability, abrasion resistance and a high poly(ethylene oxide) content are coatings of the type described in U.S. 5,077,352 (issued December 31, 1991 to R. K. Elton), the disclosure of which is incorporated herein by reference. These coatings are applied as a solution of an isocyanate, a polyol, and a high molecular weight poly(ethylene oxide).

After application of the coating, at least a portion of the solvent is removed and the coating is cured by allowing the polyol and isocyanate to react to form a crosslinked substantially polyurethane matrix associated or complexed with the poly(ethylene oxide) by hydrogen bonding. Preferably, the weight ratio of isocyanate and polyol to poly(ethylene oxide) varies from 0.25 to 6.0 and most preferably from 0.75 to 2.0. The stoichiometric ratio of total NCO groups in the isocyanate to total OH groups in the polyol may vary from 0.8 to 3.5, preferably from 0.85 to 1.5. Advantageously, when used as the coating in the

present process, the Elton coating not only has the ability to adhesively bond by crosslinking but also the ability to soften, elongate, and conform to the thermoplastic tubing when moderate heat is applied to the coated tubing during the stretching and expanding of the coated tubing to form a balloon.

The particularly preferred coating of the Elton patent is prepared by weighing appropriate quantities of isocyanate, polyol, and poly(ethylene oxide), adding them to an appropriate solvent, and adding additional solvent as needed to adjust the solids content to the desired level. Suitable organic solvents for this coating may include acetonitrile, dimethylacetone, *n*-methyl pyrrolidone, pyridine, preferably halogenated solvents such as methylene chloride, methylene bromide, dichloroethane, dibromoethane, chloroform, and trichloroethylene, and blends of the above. Solids contents in a range of from 0.4 to 40% are preferred.

Another functional poly(ethylene oxide) coating useful herein is the hydrophilic coating described in U.S. 4,459,317 (issued July 10, 1984 to H.R. Lambert), the disclosure of which is incorporated herein by reference. A first coating of unreacted isocyanate groups on the polymer surface is formed by applying a solution containing a compound having at least two unreacted isocyanate groups per molecule and then evaporating the solvent by air drying. A second coating of poly(ethylene oxide) dissolved in a solvent is then applied, the solvent is evaporated off, and finally the coating is cured, preferably for 5-30 minutes at 50-100°C in the presence of a water-containing gas such as ambient air. Known isocyanate curing catalysts may be added to one or both coating solutions. The coating normally consists of a poly(ethylene oxide) - polyurea prepolymer formed when the isocyanate groups react with water during the curing to yield an amine which rapidly reacts with other isocyanate groups to form urea crosslinks.

Suitable isocyanates include polymethylene polyphenyl isocyanate, 4,4'-diphenylmethane diisocyanate, and 2,4-toluene diisocyanate, as well as prepolymers - or other addition products of isocyanates and polyols. Suitable solvents for the isocyanate compound are ethyl acetate, acetone, chloroform, methyl ethyl ketone, ethylene dichloride, and preferably methylene chloride. The isocyanate solution may contain 0.5 to 10%, preferably 1 to 6% (weight/volume), of the isocyanate compound.

The poly(ethylene oxide) used should have a mean molecular weight of between 10⁴ and 10⁷, preferably 10⁵. A suitable poly(ethylene oxide) is sold under the trade name Polyox® by Union Carbide Corp. The preferred and suitable solvents for the poly(ethylene oxide) are the same as those

5

discussed above. The proportion of poly(ethylene oxide) is preferably between 0.5 and 10%, most preferably between 2 and 8% (weight/volume).

Examples of other useful functional poly(ethylene oxide) coatings are found in U.S. 4,980,357 (issued Feb. 5, 1991 to M. Karakella et al.). Of the several functional coatings disclosed in the '357 patent, the coatings containing poly(ethylene oxide) are useful herein for coating the thermoplastic tubing used to form dilatation balloons. Suitable coatings are uniform blends of an elastomeric segmented hydrophilic poly(urethanes) (HPEU) and poly(ethylene oxide) in an aqueous liquid. The poly(ethylene oxide) should be present in an amount of about 5 to 25 wt. %.

The HPEU is prepared from a diisocyanate, a polyether glycol, and a chain extender. Suitable diisocyanates are aromatic diisocyanates such as methylene diisocyanate (MDI), aliphatic diisocyanates, such as hexamethylene diisocyanate. The most preferred diisocyanate is MDI. The polyether glycol component may be poly(ethylene glycol) (PEG), alone or mixed with polypropylene oxide glycol or polytetramethylene oxide glycol. The preferred polyol is PEG having a molecular weight of from about 800 to 3300 or a mixture containing at least 50 wt. % thereof. The most preferred polyether glycol is a PEG having an average molecular weight of 1000 to 1450. The chain extender may be water and/or a low molecular weight branched or unbranched diol, diamine or amino alcohol of up to 10 carbon atoms or mixtures thereof. The polymer thus formed is prepared without the use of a catalyst and the resulting product is a polyurethane or a polyurethaneurea depending upon the chain extender used.

Additional examples of useful functional poly(ethylene oxide) coatings are found in U.S. 5,041,100 (issued August 20, 1991 to S.M. Rowland et al.), the disclosure of which is incorporated herein by reference. Of the poly(ethylene oxide) coatings disclosed in the Rowland et al. patent, coatings where the structural plastic is a thermoplastic, solvent-soluble linear polyurethane are useful for coating the thermoplastic tubing used for forming dilatation balloons. These coatings comprise an intimate physical mixture of 50 to 98 wt. % of the polyurethane and 2 to 50 wt. % of a poly(ethylene oxide) having a molecular weight of at least 10,000, preferably at least 1,000,000. Coatings which contain 10% to 30% poly(ethylene oxide) are most useful herein. Typically, an aqueous dispersion of the polyurethane and poly(ethylene oxide) is used. There is no need for any curing step to effect cross-linking. The coatings provide at least temporary lubricity and may be beneficially

8

employed in applications where temporary lubricity is sufficient or even desirable.

Other functional lubricious coatings useful herein include hydrophilic polyurethanes such as those disclosed in U.S. 4,158,068 and U.S. 4,158,087 (both issued May 22, 1979 to F.E. Gould); polyvinyl alcohols such as those disclosed in U.S. 4,877,901 (issued December 18, 1990 to R.F. O'Stead); hydrophilic polymers such as those described in U.S. 4,467,073 (issued August 21, 1984 to W.S. Greasy), U.S. 4,705,709 (issued November 10, 1987 to V.L. Vallancourt) and U.S. 4,876,126 (issued October 24, 1989 to N. Takemura et al.). The 068 hydrophilic polymers are polyurethane polyester resins having free hydroxyl groups and carboxylate groups in the polymer backbone. The functional protective lubricous coatings disclosed in U.S. 5,028,607 (issued June 25, 1991 to M. Kizilutas) are also useful herein. The '607 coatings comprise an aqueous dispersion of a urethane having a solids content of about 30-50% as the protective compound, a silicone or silicone emulsion having a solids content of at least about 15% as a slip additive (e.g., dimethyl siloxane), and optionally a crosslinking agent for the urethane (e.g., a polyfunctional aziridine). The disclosure of the above patents is incorporated herein by reference.

Many functional lubricious coatings used in biomedical applications contain a significant amount of polyvinyl pyrrolidone (PVP). It is expected that such coatings will be useful herein provided the PVP is adequately modified to accept the conditions of the expansion step, for example, through the use of plasticizers, PVP copolymers, or other PVP modifiers.

For all functional biomedical coatings, it is understood that certain coating additives commonly used in formulating coatings may be beneficially employed to produce a desirable result. Exemplary coating additives include surfactants or wetting agents, viscosity and flow control agents, antioxidants, pigments, and air release agents or defoamers.

Surfactants or wetting agents are used to promote wetting to the substrate as well as adhesion of the coating to the substrate. Useful wetting agents include perfluorooctyl ethoxylate mixtures, 2,4,7,9-tetraethyl 1,5-decyl-4,7-diol and ethylene oxide adduct thereof, 2,3,5-dimethyl-1, hexyn-3-ol, condensation products of ethylene oxide and diisocyanate, isooctylphenol, condensation products of stearylamine and ethylene oxide, nonylphenol ypoly(ethyleneoxy) ethanol, and polyethoxylated octylphenol.

Viscosity and flow control agents are used to adjust the viscosity and thixotropy to a desired level. Preferably the viscosity is such that the coat-

6

ing can be formed on the thermoplastic tubing at the desired thickness. Viscosities of from 50 cps to 500 cps can be used, although higher or lower viscosities may be useful in certain instances. Viscosity control agents include, but are not limited to, fumed silica, cellulose acetate butyrate and ethyl acrylate/2-ethylhexyl acrylate copolymer. Flow control agents are preferably used in amounts from 0.05 to 5 wt. % of coating.

Antioxidants are used to improve the oxidative stability of the coatings and include but are not limited to bis (3,5-di-*t*-butyl-4-hydroxybenzyl)-isocyanurate, 2,2'-methylenebis(4-methyl-6-*t*-butylphenol), 1,3,5-trimethyl-2,4,6-tris(3,5-di-*t*-butyl-4-hydroxybenzyl) benzene, butyl hydroxy toluene, octadecyl 3,5-di-*t*-butyl-4-hydroxyhydrochinonate, 4,4'-methylenebis(2,6-di-*t*-butylphenol), *p,p*-di-*t*-butylphenylamine, 1,1,3-tris-(2-methyl-4-hydroxy-5-*t*-butylphenyl) butane. Antioxidants are preferably used in amounts from 0.01 to 1 wt. % of coating.

Conventional pigments can be added to impart color or radiopacity or to increase the desired appearance of the coatings.

Air release agents or defoamers are added to quickly release air bubbles formed in the wet film during the coating operation. They include, but are not limited to, polydimethyl siloxanes, 2,4,7,9-tetraethyl-5-decyl-4,7-diol, 2-ethylhexyl alcohol, and *n*-beta-aminoethyl-gamma-amino-propyl-trimethoxysilane. Air release agents are often used in amounts from 0.005 to 0.5 wt. % of the coating. Additionally, the functional biomedical coatings may also contain an effective amount of a therapeutic agent which can diffuse out of the coating in a continuous, controlled dosage over a substantial period of time.

Specific examples of such therapeutic agents include anti-thrombogenic agents or other agents for suppressing acute thrombosis, stenosis or late restenosis in arteries. Such agents include heparin, streptokinase, urokinase, tissue plasminogen activator, anti-thromboxane B₂ agents, anti-B-thromboglobulin, prostaglandin E₂ aspirin, dipyridamole, anti-thromboxane A₂ agents, murine monoclonal antibody 7E3, triazopyrimidine, ciprostone, hirudin, ticlopidine, nicorandil, and the like. Antiplatelet derived growth factor may be used as a therapeutic agent to suppress subintimal fibromuscular hyperplasia at an arterial stenosis site, or any other inhibitor of cell growth at the stenosis site may be used.

The therapeutic agent also may comprise a vasoconstrictor to counteract vasospasm, for example, an antispasmodic agent such as papaverine. The therapeutic agent may be vasoactive agent such as calcium antagonists, or alpha and beta adrenergic agonists or antagonists.

9

10

The therapeutic agent may be an anti-neoplastic agent such as 5-fluorouracil or any known anti-neoplastic agent, optionally mixed with a controlled release carrier for the agent.

The therapeutic agent may be an antibiotic which may be applied, optionally in conjunction with a controlled release carrier for persistence, to an infected site or any other source of localized infection within the body. Similarly, the therapeutic agent may comprise steroids for the purpose of suppressing inflammation in a localized tissue site.

Also, anti-infective agents such as chlorhexidine may be added for improved infection resistance of the coated product.

The coating may contain binders such as quaternary ammonium compounds and/or amino-functional poly(ethylene oxide) to modify the release kinetics of therapeutic agents carried in the coating.

Care should be taken in adding other agents to the coating mixture. The agents should be compatible with the functional agent and the agents used should not adversely affect each other's properties.

The above functional biomedical coatings are typically applied using conventional methods. One end of the tubing is sealed and the outer surface of the tubing is coated using a method such as dipping, spraying, wiping, painting or the like. Preferably, the tubing is dipped at about 20-25 °C and less than 60% relative humidity. Coating thickness and functionality can be affected by withdrawal rate of the tubing from the coating mixture.

After applying the coating, the carrier is allowed to evaporate from the coated thermoplastic tubing, often by exposure to ambient conditions for a suitable drying time, typically from 15 to 480 minutes, or the tubing is dried at temperatures of 10 to 205 °C from for a few seconds to 48 hours. The time and temperature selected will, of course, depend upon the carrier used and the speed with which evaporation is desired. In all cases the drying conditions should be non-deleterious to the underlying thermoplastic tubing.

The coated thermoplastic tubing is fabricated into an expanded product using the conventional stretching and expanding steps used in blow molding. One skilled in the art will select the proper conditions, which will depend on the type of thermoplastic tubing coated and the type of functional coating applied. In most cases, the stretched tubing is heated during stretching and expansion.

When a coated dilatation balloon is being prepared by blow molding, the process described in U.S. Pat. 3,298,3 (reissued July 31, 1969) to S.B. Levy) is typically used. The process described in the '983 patent is carried out by drawing at a suitable temperature a polymeric tubing having a finite length (L₁) and an internal diameter (ID₁) to a length (L₂) which is 3 to 6 L₁, then expanding the

drawn tubing of internal diameter (ID₁) which is 5-8 ID, followed by cooling the drawn and expanded tubing to less than the second order transition temperature. The process can be carried out in conventional equipment. A mold having a cavity with dimensions commensurate with the desired size of the balloon to be produced is typically used. The open end of the tubing is equipped with a suitable fitting so that a pressurized fluid (e.g., a gas such as nitrogen) can be introduced into the tubing during the expansion step. If the tubing extends beyond the mold, the use of a restraining means is preferred to maintain the dimensions of the tubing in the region outside the mold while the pressure is being applied to the inside wall of the tubing. After the drawn tubing is positioned in the mold, heat is applied to raise the tubing's temperature. A suitable temperature is one within the range extending from the second order transition temperature to the first order transition temperature of the thermoplastic polymer used for the tubing. Similar temperatures can be used for both the drawing and expanding steps. The desired temperature can be achieved by any suitable heat generating means. For polyethylene terephthalate (PET) the preferred temperature is 84-99 °C. For polyurethanes the temperature will vary depending upon the polyurethane's composition and the desired characteristic of the final product.

It will be understood by one skilled in the art that some adjustments in the drawing and expansion ratios and in the drawing and expansion temperatures may be necessary to fabricate balloons. One skilled in the art will recognize that, although the tube drawing step is typically performed prior to the tube expansion step, the latter can be performed immediately after the drawing of the tubing, or it can be performed at a later time.

Because of the recovery characteristics of shaped polymeric structures which are drawn by the above procedures, it may be necessary to maintain axial tension on the drawn tubing during the expansion step.

The coated balloons are attached to the catheters using conventional methods such as crosslinking adhesives, hot melt adhesives, plastic welding, or the like. Typically, the catheters are not coated.

The present process can be used to coat the inflatable annular portion of integral dilatation catheters such as the combination guiding catheter-dilatation catheter assembly described in U.S. Pat. 4,323,071 (issued April 6, 1982) to J.B. Simpson et al.

The assembly is formed of two heat-shrinkable irradiated modified polyolefin tubes with the first tube being coaxially disposed within the second tube in such a manner that the second tube surrounds the first tube. Near the distal end of the second tube there is a balloon-like or inflatable

annular portion. An annular flow passage is formed between the second tube and extends from the proximal end into the balloon-like or inflatable annular portion to permit the introduction of an expansion fluid into the balloon-like portion for inflating the balloon-like portion and for withdrawing the expansion fluid to deflate the balloon-like portion. The second tubular member is then progressively heated along its length in a suitable manner, such as by a hot air tool to a suitable temperature of about 120 °. The second tube shrinks and forms a tight seal with respect to the first tube. Alternative methods for forming the catheter are disclosed in the '071 patent, the disclosure of which is incorporated herein by reference. Alternatively, the entire second tube of the combination can be coated instead of just the balloon. Any of the above functional biomedical coatings can be used and the balloon can then be inflated in the conventional manner.

It should be understood that the foregoing description of the invention is intended merely to be illustrative and that other embodiments and modifications may be apparent to those skilled in the art without departing from the spirit of the invention.

Example 1

a. Preparation of Premix

A poly(ethylene oxide) premix in methylene chloride was prepared by adding to about 3658 g. of methylene chloride about 132 g. of a poly(ethylene oxide) marketed under the trade name POLYOX® WSR N-750 NF resin. The POLYOX® WSR N-750 NF resin is a water-soluble resin (CAS Registry No. 25372-69-3) with an approximate molecular weight of 300,000. The mixture was rolled at 6-10 rpm for at least 24 hours. If the resulting solution was not uniform (i.e., if any lumps or gels were present), the lumps or gels were broken up, and the solution was allowed to stand for 24 hours. The solution was then rolled for about 60 minutes to form a uniform solution of 3.3 wt. % total solids.

b. Preparation of Coating

The final coating was prepared by adding a polyester polyol and an aromatic poly(isocyanate) to the poly(ethylene oxide) premix. The polyester polyol used was Mullion-R-18, which is available from the Coatings Division of Miles Corp. Mullion-R-18 is polyester resin having a hydroxyl number of 57-63, acid number of 1.2 maximum, water content of 0.10 wt. % maximum, Gardner color of No. 2 maximum, and viscosity at 75 °C of 900-1600 mPa's. Typically, the colorless to light yellow liquid has a OH content of 1.8%, average equivalent

weight of 935, specific gravity of 1.19 @ 5 °C, weight per gallon of 9.9 lbs., viscosity @ 20 °C of 26,000 mPa's, and flash point (Pensky-Martens closed cup) of 204 °C (400 °F). The isocyanate used was Mondur CB-60 which is available from the Coatings Division of Miles Corp. Mondur CB-60 is an aromatic polyisocyanate adduct based on toluene diisocyanate (TDI) dissolved in propylene glycol monomethyl ether acetate (PMA) and xylene (25:15). It has a solids content of 80 ± 2 wt. %, NCO content of 10.0 - 10.8%, Gardner color of No. 4 maximum, viscosity @ 20 °C of 150-500 mPa's, and free TDI monomer content of 0.7% maximum. Typically, the clear, slightly yellow liquid has an equivalent average weight of 404, specific gravity @ 25 °C of 1.13, weight of 9.4 lbs. per gallon, and flash point of 28 °C (82 °F).

A total of 6.72 g. of the polyester polyol was added to an appropriately sized container. Then 3.22 g. of the isocyanate were added, followed by 285.3 g. of the poly(ethylene oxide) premix and then by 421.7 g. of methylene chloride. The resulting mixture was mixed on a roller for at least 5 minutes and until it was visually homogeneous. The coating solution had a total solids content of about 3 wt. %.

c. Application of the Coating

Thermoplastic polyurethane tubings having inner diameters ranging from 0.0077 to 0.0238 in., wall thicknesses ranging from 0.0037 to 0.0119 in., and outer diameters ranging from 0.0151 to 0.0476 were heat sealed at one end. The tubing used was PELLETHANE® 2363-75D available from Dow Chemical Co. PELLETHANE® 2363-75D is a polyether polyurethane resin used for extrusion and injection molding. Typically, it has a melt index of about 34 gmv/10 min. (224 °C, 5000 g.). Durometer D hardness of 74 ± 4; specific gravity of 1.21; tensile modulus of 165,000 psi; ultimate tensile strength of 6980 psi; ultimate elongation of 250%; tear strength (Die C) of 14 pli; heat distortion temperatures of 65 and 55 at 66 and 264 psi, respectively; Taber abrasion (H-22 wheel, 1000 g. weight, 1000 cycles) of 55 mg. loss; Clash-Berg Modulus (IT) of +9 °C; and flexural modulus of 180,000 psi. The ASTM test methods used are as follows: D-1238 for melt index; D-2240 for hardness; D-792 for specific gravity; D-412 for tensile modulus, ultimate tensile strength and ultimate elongation; D-824 for tear strength; D-648 for heat distortion temperature; D-1044 for Taber abrasion; D-1043 for Clash-Berg modulus; and D-790 for flexural modulus.

The coating was applied by dipping the tubing in the above solution. The tubing was introduced at a rate of about 25 inches per minute and withdrawn

optionally propylene; and polyether polyamide block copolymers and wherein the coating is a lubricious coating.

diamine or an amino alcohol of up to carbon atoms, and mixtures thereof.

31. The process of Claim 23, wherein the coating is an intimate physical mixture of about 50-98% by weight of a polyurethane and about 2-50% by weight of a poly(ethylene oxide) having a molecular weight of at least 10,000 in a carrier.

21. The process of Claim 20, wherein the orienting step includes heating the coated tubing to a temperature within the range extending from the second order transition temperature to the first order transition temperature of the thermoplastic polymer.

22. The process of Claim 21, further comprising the step of drawing the oriented section to provide a drawn oriented section, followed by expanding the drawn oriented section to a modified profile and size, further followed by heat setting the modified profile and size to form the coated balloon.

32. The process of Claim 31, wherein the polyurethane is a aliphatic polyurethane and the carrier is water.

33. The process of Claim 23, wherein the coating is a crosslinked polyurethane matrix associated or complexed with a poly(ethylene oxide).

34. The process of Claim 33, wherein the polyurethane matrix is prepared by coating the tubing with a solution consisting essentially of an isocyanate, a polyol, and the polyethylene oxide dissolved in a suitable solvent.

35. The process of Claim 32, wherein the isocyanate is selected from the group consisting of 2,4- and 2,6-toluene diisocyanate and prepolymer thereof, hexamethylene diisocyanate and prepolymer thereof, diphenylmethane 4,4'-diisocyanate and prepolymer thereof, bis(4-isocyanatocyclohexyl) methane and prepolymer thereof, and isophorone diisocyanate and prepolymer thereof, wherein the polyol is selected from the group consisting of polyol selected from the group of castor oil and castor oil derivatives, saturated polyester polyols, polyether polyols, unsaturated polyester polyols, polyacrylate polyols; wherein the poly(ethylene oxide) has a molecular weight of about 10,000-5,000,000 and wherein the solvent is selected from the group consisting of solvents methylene chloride, dibromomethane, dichloroethylene, trichloroethylene, pyridine, n-methyl pyrrolidone, dioxolane, acetonitrile, and blends of the above.

36. The lubricious dilatation balloon prepared by the process of Claim 20.

37. The lubricious dilatation balloon produced by the process of Claim 36, wherein the coating is an abrasion resistant, hydrophilic, lubricious coating which is a continuous film of a crosslinked substantially polyurethane matrix complexed or associated with a poly(ethylene oxide).

lected from the group consisting of polyurethane precursors and polyurea precursors.

6. The process according to Claim 5, wherein the coating comprises a crosslinked polyurethane matrix.

7. The uniformly functionally coated expanded thermoplastic medical product prepared by the process of Claim 1.

8. The uniformly functionally coated expanded thermoplastic medical product prepared by the process of Claim 3.

9. The uniformly functionally coated expanded thermoplastic medical product prepared by the process of Claim 4.

10. The uniformly functionally coated expanded thermoplastic medical product prepared by the process of Claim 5.

11. The uniformly functionally coated expanded thermoplastic medical product prepared by the process of Claim 6.

12. A process for preparing a coated balloon, which comprises the steps of:

(a) applying to at least a portion of an inner and/or an outer surface of an expandable thermoplastic tubing at least one adherent lubricious coating which comprises at least one lubricious agent and a carrier;

(b) allowing the coated tubing to dry at a time and temperature sufficient to remove at least part of the carrier; and

(c) stretching and/or expanding the dried coated tubing with an inflating fluid at a pressure sufficient to form the coated balloon.

13. The process of Claim 12, further comprising the step of heating the partially dried coated tubing at a temperature and for a time sufficient to soften the coated tubing prior to stretching and/or expansion.

14. The process of Claim 12, wherein the tubing is selected from the group consisting of polyethylene; polypropylene; polyethylene terephthalate; polybutylene terephthalate; polyvinyl chloride; polyimides; polyetherimides; polyamides; polyamideimides; polycarbonates; monomers; polyaryl ether ketones; polyurethane; ethylene-vinyl acetate copolymers; ethylene-butylene-styrene block copolymers admixed with low molecular weight styrene and

21. The process of Claim 20, wherein the orienting step includes heating the coated tubing to a temperature within the range extending from the second order transition temperature to the first order transition temperature of the thermoplastic polymer.

22. The process of Claim 21, further comprising the step of drawing the oriented section to provide a drawn oriented section, followed by expanding the drawn oriented section to a modified profile and size, further followed by heat setting the modified profile and size to form the coated balloon.

23. The process of Claim 20, wherein the tubing is selected from group consisting of polyethylene; polypropylene; polyethylene terephthalate; polybutylene terephthalate; polyvinyl chloride; polyimides; polyetherimides; polyamides; polyamideimides; polycarbonates; monomers; polyaryl ether ketones; polyurethane; ethylene-vinyl acetate copolymers; ethylene-butylene-styrene block copolymers admixed with low molecular weight styrene and optionally propylene; and polyether polyamide block copolymers.

24. The process of Claim 23, wherein the tubing is polyethylene terephthalate.

25. The process of Claim 23, wherein the tubing is polyurethane.

26. The process of Claim 23, wherein the tubing is a segmented polyurethane.

27. The process of Claim 23, wherein the segmented polyurethane contains at least 45 wt.% of soft segments with the balance being hard segments.

28. The process of Claim 23, wherein the carrier is selected from the group consisting of water, methylene chloride, methylene bromide, trichloroethylene, ethylene dichloride, N-methylpyrrolidone, pyridine, and mixtures thereof.

29. The process of Claim 23, wherein the polymer is polyurethane or polyurethane-urea which is prepared from a diisocyanate, a polyether glycol, and a chain extender.

30. The process of Claim 29, wherein the diisocyanate is methylene diisocyanate, the polyether glycol is polyethylene glycol, and the chain extender is selected from the group consisting of water, a low molecular weight diol, a

38. The lubricious dilatation balloon of Claim 37, wherein the crosslinked polyurethane matrix is formed in situ by the reaction of a polyester polyol and toluene diisocyanate in the presence of the polyethylene oxide, with the polyethylene oxide having a molecular weight of above about 50,000.

EUROPEAN SEARCH REPORT

DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim
Y	EP-A-0 214 721 (FRANKLIN MEDICAL LIMITED) * column 4 - column 9; claims *	1-38
Y	EP-A-0 454 293 (C.R. BARD, INC.) * column 3, line 28 - column 6, line 48; claims; examples *	1-38
D	US-A-5 077 352 (R. ELTON)	
A	WO-A-92 11877 (UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION) * claims *	4
A	EP-A-0 093 094 (ASTRA MEDITEC AB)	
D	US-A-4 459 317 (H. LAMBERT)	
A, D	US-A-5 026 607 (M. KIEZULAS)	
TECHNICAL FEATURES RELEVANT		A61L

The present search report has been drawn up for all claims

Date of completion of the search
10 January 1994

Examiner
Cousins-Van Steen, G

Place of search
THE HAGUE

CATEGORY OF CITED DOCUMENTS
I : theory or principle underlying the invention
C : earlier patent document, not published as yet
P : prior art document
Y : particularly relevant if combined with another document
A : document of the same category
D : document of the same category
O : non-written disclosure
P : prior art document